KARD Stock Forecast: Kardigan, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Kardigan, Inc. is $43. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 3 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Kardigan, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (54): Analysts have, on balance, been raising their forecasts.
Volatility (4): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
KARD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KARD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Leerink Partners | Maintains | Outperform | $37 → $36 |
| 4 Nov 2026 | HC Wainwright & Co. | Initiates | Buy | $42 |
| 29 Oct 2026 | Cantor Fitzgerald | Initiates | Overweight | $50 |
| 22 Oct 2026 | Baird | Initiates | Outperform | $43 |
| 16 Oct 2026 | William Blair | Initiates | Outperform | — |
| 12 Oct 2026 | UBS | Initiates | Buy | $25 |
| 25 Aug 2026 | JP Morgan | Maintains | Overweight | $51 → $46 |
| 13 July 2026 | Jefferies | Initiates | Buy | $40 |
| 13 July 2026 | JP Morgan | Initiates | Overweight | $51 |
| 13 July 2026 | Leerink Partners | Initiates | Outperform | $37 |
| 13 July 2026 | TD Cowen | Initiates | Buy | $46 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KARD.
This page is one stock. Monday covers all of them.
KARD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
KARD vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
KARD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.9×
- EV / EBITDA
- —
Cheaper than 46% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −49.1%
- Dividend yield
- —
Higher than 8% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kardigan, Inc. has a market value of $1.1B and an enterprise value of $622.5M.
Kardigan, Inc. employs 241 people.
Data provided by Twelve Data
KARD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at KARD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Kardigan, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about KARD
What is the KARD stock price forecast for 2026-2027?
The median 12-month analyst price target for Kardigan, Inc. is $43, with estimates ranging from $25 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KARD stock a buy right now?
Of the 9 analysts covering Kardigan, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kardigan, Inc. 3 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KARD?
As at 21 Nov 2026, Kardigan, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (54 of 100).
Will KARD stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts is $43, and Ticker Nerd's factor model ranks Kardigan, Inc. 3 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KARD stock forecast for 2030?
No analyst covering Kardigan, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KARD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $50 over the next 12 months.
What does Kardigan, Inc. do?
Kardigan Inc. is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company works on targeted therapies designed to address the underlying disease mechanisms behind specific heart conditions, including cardiomyopathies that can lead to heart failure.
About Kardigan, Inc.
Kardigan Inc. is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company works on targeted therapies designed to address the underlying disease mechanisms behind specific heart conditions, including cardiomyopathies that can lead to heart failure. Its current pipeline centers on clinical-stage cardiovascular programs aimed at diseases where approved treatment options remain limited or unavailable. Kardigan also uses a research and translational platform that combines clinical data, analytics, and precision medicine approaches to support drug discovery and development. The company operates as a single segment business centered on cardiovascular therapeutics and serves the broader healthcare and biotechnology market. Kardigan Inc. is headquartered in Princeton, New Jersey, and maintains its operational base in South San Francisco, California.
CEO Mr. Tassos Anastasios E. Gianakakos M.Sc., MBA · 241 employees · United States · https://www.kardigan.bio